<![CDATA[Merck KGaA 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=23289>Wed, 29 Apr 2026 12:50:56 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Merck Appoints David Weinreich as New Global Head of R&D and Chief Medical Officer for Healthcare Business Sector]]>https://www.newswire.co.kr/newsRead.php?no=1017920Wed, 03 Sep 2025 09:53:58 +0900<![CDATA[Pimicotinib Demonstrates Best-in-Class Potential with Significant Efficacy and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumor]]>https://www.newswire.co.kr/newsRead.php?no=1012118Thu, 29 May 2025 09:14:15 +0900<![CDATA[Merck Showcases Innovation in Advanced Cancers and Rare Tumors at ASCO 2025]]>https://www.newswire.co.kr/newsRead.php?no=1011777Fri, 23 May 2025 11:30:09 +0900<![CDATA[Merck Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE) with Active Lupus Rash]]>https://www.newswire.co.kr/newsRead.php?no=1011640Thu, 22 May 2025 08:40:00 +0900<![CDATA[Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial]]>https://www.newswire.co.kr/newsRead.php?no=1000594Tue, 12 Nov 2024 15:38:50 +0900<![CDATA[Merck Unveils New MAVENCLAD® Four-Year Data Highlighting Benefits of Early Treatment and Sustained Efficacy Across Multiple Measures of Disease Activity]]>https://www.newswire.co.kr/newsRead.php?no=996836Fri, 13 Sep 2024 08:55:20 +0900<![CDATA[Merck Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)]]>https://www.newswire.co.kr/newsRead.php?no=995889Fri, 30 Aug 2024 08:39:26 +0900<![CDATA[Merck Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer]]>https://www.newswire.co.kr/newsRead.php?no=992162Tue, 25 Jun 2024 09:43:32 +0900<![CDATA[Merck’s Innovative Oncology Pipeline of DNA Damage Response Inhibitors and Antibody-Drug Conjugates Poised to Advance Cancer Treatment]]>https://www.newswire.co.kr/newsRead.php?no=990953Tue, 04 Jun 2024 09:32:06 +0900<![CDATA[Merck Signs MoU with KAIST to Advance Scientific Collaboration]]>https://www.newswire.co.kr/newsRead.php?no=990656Thu, 30 May 2024 10:15:25 +0900<![CDATA[Merck to Showcase Advances in the Science of Cancer With New Data Presented at ASCO 2024]]>https://www.newswire.co.kr/newsRead.php?no=990341Fri, 24 May 2024 14:10:00 +0900<![CDATA[Merck Invests More than € 300 Million in New Life Science Production Site in Korea]]>https://www.newswire.co.kr/newsRead.php?no=986346Thu, 21 Mar 2024 13:29:58 +0900<![CDATA[Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma]]>https://www.newswire.co.kr/newsRead.php?no=983052Tue, 23 Jan 2024 11:50:00 +0900<![CDATA[Merck Expands Colorectal Cancer Portfolio Through Licensing Agreement with Inspirna]]>https://www.newswire.co.kr/newsRead.php?no=982170Fri, 05 Jan 2024 10:30:00 +0900<![CDATA[Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis]]>https://www.newswire.co.kr/newsRead.php?no=980366Wed, 06 Dec 2023 13:45:00 +0900<![CDATA[Merck Strengthens Oncology Portfolio Through Commercialization Agreement With Abbisko for Phase III Asset, Pimicotinib]]>https://www.newswire.co.kr/newsRead.php?no=980222Tue, 05 Dec 2023 10:10:00 +0900<![CDATA[Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate]]>https://www.newswire.co.kr/newsRead.php?no=977526Mon, 30 Oct 2023 17:37:10 +0900<![CDATA[Merck to Present Latest Research from Oncology Portfolio at ESMO 2023]]>https://www.newswire.co.kr/newsRead.php?no=976375Mon, 16 Oct 2023 15:35:00 +0900<![CDATA[Evobrutinib, CNS-Penetrant BTKi, Has Shown Sustained Clinical Benefit Up to Five Years in People with RMS]]>https://www.newswire.co.kr/newsRead.php?no=976067Wed, 11 Oct 2023 15:38:40 +0900<![CDATA[Merck Presents New MAVENCLAD® (Cladribine Tablets) Data Highlighting Sustained Reduction in NfLs and Benefit of Early Initiation]]>https://www.newswire.co.kr/newsRead.php?no=975953Tue, 10 Oct 2023 15:59:09 +0900<![CDATA[Merck Launches New Collaboration with United Nations-Guided Global Initiative on Ageing to Support Carers]]>https://www.newswire.co.kr/newsRead.php?no=975770Fri, 06 Oct 2023 11:04:14 +0900<![CDATA[Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery]]>https://www.newswire.co.kr/newsRead.php?no=974847Wed, 20 Sep 2023 14:29:30 +0900<![CDATA[Merck Highlights Commitment to Improving Cancer Outcomes at ASCO 2023]]>https://www.newswire.co.kr/newsRead.php?no=967637Fri, 26 May 2023 11:55:00 +0900<![CDATA[Initiation of New Patients on Evobrutinib Paused in the U.S.; Fully Enrolled Phase III Evobrutinib Studies Continue]]>https://www.newswire.co.kr/newsRead.php?no=965024Wed, 12 Apr 2023 16:30:00 +0900<![CDATA[Merck Strengthens Oncology Franchise by Securing Exclusive Worldwide Rights to Anti PD-L1 Antibody BAVENCIO® (avelumab)]]>https://www.newswire.co.kr/newsRead.php?no=963971Tue, 28 Mar 2023 09:40:00 +0900